Carmen Pilar Simeón-Aznar

Dr. Carmen Pilar Simeón-Aznar

orcid

Research Focus & Metrics

Academic Career Length

39Years (1988-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2014 in Seminars in Arthritis and Rheumatism
Verified
Journal Article
Closed access
MRManuel Rubio-Rivas
Manuel Rubio-Rivas
CRCristina Royo-Cebrecos
Cristina Royo-Cebrecos
CSCarmen Pilar Simeón-Aznar
Carmen Pilar Simeón-Aznar
XCXavier Corbella
Xavier Corbella
VFVicent Fonollosa
Vicent Fonollosa

31 October 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
ELELENA LÓPEZ-ISAC
ELENA LÓPEZ-ISAC
MAMarialbert Acosta-Herrera
Marialbert Acosta-Herrera
MKMartin Kerick
Martin Kerick
SAShervin Assassi
Shervin Assassi
ASAnsuman T. Satpathy
Ansuman T. Satpathy
Javier MartínJavier Martín
Javier Martín
Systemic sclerosis (SSc) is an autoimmune disease that shows one of the highest mortality rates among rheumatic diseases. We perform a large genome-wide association study (GWAS), and meta-analysis with previous GWASs, in 26,679 individuals and identify 27 independent genome-wide associated signals, including 13 new risk loci. The novel associations nearly double the number of genome-wide hits reported for SSc thus far. We define 95% credible sets of less than 5 likely causal variants in 12 loci. Additionally, we identify specific SSc subtype-associated signals. Functional analysis of high-priority variants shows the potential function of SSc signals, with the identification of 43 robust target genes through HiChIP. Our results point towards molecular pathways potentially involved in vasculopathy and fibrosis, two main hallmarks in SSc, and highlight the spectrum of critical cell types for the disease. This work supports a better understanding of the genetic basis of SSc and provides directions for future functional experiments.

1 July 2005 in Lupus
Verified
Journal Article
Closed access
ASAlbert Selva-O'Callaghan
Albert Selva-O'Callaghan
MLM Labrador-Horrillo
M Labrador-Horrillo
XMX Muñoz-Gall
X Muñoz-Gall
XMXavier Martínez-Gómez
Xavier Martínez-Gómez
JMJ Majó-Masferrer
J Majó-Masferrer
MVM Vilardell-Tarrés
M Vilardell-Tarrés
The objective of this study was to assess the prevalence, clinical, histological and immunological characteristics, and the long-term outcome of polymyositis-(PM) and dermatomyositis-(DM) associated lung disease, and to define subgroups of lung-associated inflammatory myopathies. This retrospective study included 81 consecutive patients diagnosed with PM/DM. Pulmonary involvement was systematically investigated in relation to clinical symptoms by chest radiography, high resolution computed tomography and pulmonary function testing. Anti-synthetase autoantibodies (ASA) were analysed by ELISAandconfirmedbyproteinandRNA immunoprecipitation methods. Statistical analyses were done with the Student t-test and Fisher exact test. Cumulative survival probabilities were estimated by the Kaplan-Meier method and Cox regression analysis. Fifty patients (61%) presented pulmonary involvement. Thirty-two (39%) had interstitial lung disease and five of them had devastating acute interstitial pneumonia with pneumomediastinum and an unfavorable prognosis. Histology showed diffuse alveolar damage in this subgroup and ASA were negative. Eighteen patients (22%) presented restrictive myopathic lung disease; in three of them respiratory muscles could not maintain ventilation. ASA were positive in 17 of the 50 patients (34%) and were significantly associated with interstitial lung disease (OR: 4.5 [95% CI: 1.3-15.3]), arthritis (OR: 6.0 [95% CI: 1.3-29.2]) and ‘mechanic hands’ (OR: 8.5 [95% CI: 1.7-41.4]); the presence of these autoantibodies did not imply worse survival prognosis. We concluded that clinical and immunological characteristics allowed the grouping of patients into different types of PM/DM lung-associated disease. Presence of ASA did not affect survival. ASA-negative patients with acute interstitial pneumonitis and pneumomediastinum had an unfavorable prognosis.

29 September 2006 in Arthritis Care & Research
Verified
Journal Article
Open access
PDF file
ASAlbert Selva-O'Callaghan
Albert Selva-O'Callaghan
MLMoisés Labrador‐Horrillo
Moisés Labrador‐Horrillo
RSRoser Solans‐Laque
Roser Solans‐Laque
CSCarmen Pilar Simeón-Aznar
Carmen Pilar Simeón-Aznar
XMXavier Martínez-Gómez
Xavier Martínez-Gómez
MVMiquel Vilardell‐Tarrés
Miquel Vilardell‐Tarrés
Objective: To determine the prevalence of myositis‐specific autoantibodies (MSAs) and myositis‐associated autoantibodies (MAAs) and their clinical and immunogenetic correlations in Mediterranean patients with idiopathic inflammatory myopathies.Methods: Sera from 88 patients were studied for MSAs and MAAs by RNA and protein immunoprecipitation. HLA typing was performed by sequence‐specific primer– and sequence‐specific oligonucleotide–polymerase chain reaction and serology. Statistical analyses were performed with Student's t‐test and Fisher's exact test. Cumulative survival probabilities were estimated by the Kaplan‐Meier method and Cox regression analysis.Results: Twenty‐eight patients (30%) had MSAs, most commonly antisynthetase antibodies (23.9%). Six patients (7.5%) had anti–Mi‐2 antibodies. No anti–signal recognition particles were found. Arthritis, mechanic's hands, interstitial lung disease, and sicca syndrome were more prevalent in patients with antisynthetase antibodies. Dysphagia and the need for more treatment courses were more frequent in patients who were anti–Mi‐2 positive. Forty‐three patients (48%) had MAAs, 20 (22%) with anti–Ro 60 and 18 (20.4%) with anti–Ro 52. Ten patients (11.4%) were positive for anti–PM‐Scl, 6 (6.8%) for anti‐RNP, and 1 for anti‐Ku antibodies. Patients with PM‐Scl, RNP, or Ro antibodies were more often classified as having overlap syndrome. Immunogenetic studies found a significant association between HLA–DR3 and the presence of antisynthetase antibodies (P = 0.049), anti–PM‐Scl antibodies (P = 0.017), and interstitial lung disease (P = 0.03). No statistically significant differences in mortality, survival, or clinical course were observed between patients positive for MSAs or MAAs and the remaining patients.Conclusion: These results are consistent with those from other published series, although some differences warrant consideration. Autoantibody studies may be useful for defining more homogeneous groups of patients with idiopathic inflammatory myopathies.

1 June 2012 in Seminars in Arthritis and Rheumatism
Verified
Journal Article
Closed access
CSCarmen Pilar Simeón-Aznar
Carmen Pilar Simeón-Aznar
VFVicent Fonollosa-Plá
Vicent Fonollosa-Plá
CTCarles Tolosa-Vilella
Carles Tolosa-Vilella
GEGerard Espinosa-Garriga
Gerard Espinosa-Garriga
MRManuel Ramos-Casals
Manuel Ramos-Casals
MVMiquel Vilardell-Tarrés
Miquel Vilardell-Tarrés

1 October 2015 in Medicine
Verified
Journal Article
Open access
CSCarmen Pilar Simeón-Aznar
Carmen Pilar Simeón-Aznar
VFV. Fonollosa-Plá
V. Fonollosa-Plá
CTCarles Tolosa-Vilella
Carles Tolosa-Vilella
GEG. Espinosa-Garriga
G. Espinosa-Garriga
MCM. Campillo-Grau
M. Campillo-Grau
MVM. Vilardell-Tarrés
M. Vilardell-Tarrés
Systemic sclerosis (SSc) is a rare, multisystem disease showing a large individual variability in disease progression and prognosis. In the present study, we assess survival, causes of death, and risk factors of mortality in a large series of Spanish SSc patients. Consecutive SSc patients fulfilling criteria of the classification by LeRoy were recruited in the survey. Kaplan-Meier and Cox proportional-hazards models were used to analyze survival and to identify predictors of mortality. Among 879 consecutive patients, 138 (15.7%) deaths were registered. Seventy-six out of 138 (55%) deceased patients were due to causes attributed to SSc, and pulmonary hypertension (PH) was the leading cause in 23 (16.6%) patients. Survival rates were 96%, 93%, 83%, and 73% at 5, 10, 20, and 30 years after the first symptom, respectively. Survival rates for diffuse cutaneous SSc (dcSSc) and limited cutaneous SSc were 91%, 86%, 64%, and 39%; and 97%, 95%, 85%, and 81% at 5, 10, 20, and 30 years, respectively (log-rank: 67.63, P < 0.0001). The dcSSc subset, male sex, age at disease onset older than 65 years, digital ulcers, interstitial lung disease (ILD), PH, heart involvement, scleroderma renal crisis (SRC), presence of antitopoisomerase I and absence of anticentromere antibodies, and active capillaroscopic pattern showed reduced survival rate. In a multivariate analysis, older age at disease onset, dcSSc, ILD, PH, and SRC were independent risk factors for mortality. In the present study involving a large cohort of SSc patients, a high prevalence of disease-related causes of death was demonstrated. Older age at disease onset, dcSSc, ILD, PH, and SRC were identified as independent prognostic factors.